Sangamo Therapeutics Files Chapter 11, Sells ST-920 Asset to PTC

What Happened Sangamo Therapeutics, Inc. announced it is operating under Chapter 11 bankruptcy protection (filed June 23, 2026, Case No. 26-10989) and, on September 17, 2026, completed the sale of substantially all assets related to ST-920 (isaralgagene civaparvovec), an AAV gene therapy candidate for Fabry disease, to PTC Therapeutics, Inc. The sale followed a court-approved bidding process and auction; the Bankruptcy Court entered the Sale Order on September 2, 2026, and the Asset Purchase Agreement is dated August 25, 2026.

Key Details

• Chapter 11 petition filed June 23, 2026 (U.S. Bankruptcy Court, District of Delaware, Case No. 26-10989).
• Purchased assets sold to PTC closing: September 17, 2026. Purchase consideration: $111,000,000 cash at closing plus up to $100,000,000 contingent on specified milestones.
• Assets sold are primarily related to ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy candidate for Fabry disease; PTC will assume certain specified liabilities.
• Company’s common stock has been suspended from Nasdaq, received a delisting notice, and is trading on the OTCID Basic Market under the symbol “SGMOQ”; the company cautions trading is highly speculative and may not reflect any recovery to holders in the Chapter 11 case.

Why It Matters This is a material restructuring step: Sangamo’s Chapter 11 case and the court-approved sale transfer a key development-stage asset and generate immediate cash ($111M) plus potential future milestone payments (up to $100M). The transaction reduces Sangamo’s asset base and shifts ST-920’s development to PTC under assumed liabilities, while the company remains a debtor-in-possession under court supervision. For retail investors, the company’s Nasdaq suspension, delisting notice, and OTC trading status mean share prices are likely disconnected from creditor recoveries in the bankruptcy — the company explicitly urges extreme caution regarding investment in its common stock.